USPTO serial 76272025
JERINI
Reviewed by CopyMark Law Group
Reg. 2894095Status 710
- Filing date
- Status date
- Registration date
- Oct 19, 2004
- Examiner
- JOHNSON, AISHA CLARKE
- Law office
- POST REGISTRATION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with JERINI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
BERLIN FED. REP., DD
BERLIN FED. REP., DD
BERLIN FED. REP., DD
12489 Berlin, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Matthew J. Smith
Matthew J. Smith Polsinelli Shughart PC100 S. Fourth St.Suite 1100St. Louis, MO 63102Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and science, agriculture, horticulture and forestry, namely, proteins, peptides, peptidomimetics, small molecules, nucleic acids and polynucleotides; proteins and recombinant proteins for scientific research use; peptides for scientific research use; antibodies for scientific research use; DNA probes for scientific research use; oligonucleotides for scientific research use; antisense constructs for scientific research use; arrays of nucleic acids on a carrier material for scientific research use; arrays of proteins on a carrier material for scientific research use; arrays of peptides on a carrier material for scientific research use | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical and veterinary products, namely, preparations for sanitation, slimming, appetite suppressants, pharmaceuticals for acidosis therapeutics, analeptic and antihypoxaemics; analgesics and antirheumatic drugs, pharmaceuticals functioning as antihelmintics, antiallergics, antianemia drugs, antiarrhythmics, antibiotics and antiinfectives, antidementics, nootropics, antidiabetics, antidotes for the treatment of poisoning, antiemetics and antivertiginosics, antiepileptics, antihemorrhagics, antifibrinolytics, hemostatics, antihypertonics, antihypoglycemics, antihypotonics, anticoagulants, antimycotics, pharmaceuticals functioning as antiparasitics, antiphlogistics, antitussives, expectorants for use in atherosclerosis, balneotherapeutics and pharmaceuticals for thermal therapy, pharmaceuticals functioning as beta receptor blocking agents, pharmaceuticals for calcium channel blocking and inhibiting of the renin angiotensin-system, pharmaceuticals functioning as broncholytics, antiasthmetics cholagoguegics and for use in biliary tract therapeutics; pharmaceuticals functioning as cholinergics, corticoids, dermatics; all purpose disinfectants and antiseptics; pharmaceuticals functioning as dietetic agents and in alimentary therapeutics; diagnostic preparations functioning as diuretics, as agents for favoring blood flow, as withdrawal agents, as fibrinolytics, to treat gout, the flu and catarrhal fever; pharmaceuticals for the treatment of gynecological illnesses, namely, menstrual cramps, hemorrhoids, hepatitis; pharmaceuticals functioning as hypnotics and sedatives; pharmaceuticals to treat cardiac ailments; pharmaceuticals for use in caries and parodontosis; dental preparations, namely, dental abrasives; laxatives, pharmaceuticals functioning as antilipaemics, local anesthetics, neural therapeutics, gastrointestinal preparations, pharmaceuticals to treat migraines; pharmaceutical preparations for use in mouth and pharyngeal therapeutics; pharmaceuticals for use as muscle relaxants; pharmaceuticals for the treatment of addiction to narcotics; pharmaceuticals for use in neuropathology; ophthalmic pharmaceuticals for treating blindness, conjunctivitis, cataract, glaucoma, retinal detachment, stye, chalazion, dacryoadenitis, corneal clouding, keratitis, gasserian ganglionitis, vitreous opacity, amaurosis, retinopathy, central retinal artery occlusion, retinoblastoma, melanoma, optic neuritis, optic nerve atrophy; pharmaceuticals for use in osteoporosis and calcium metabolism modification; pharmaceuticals for the treatment of Parkinson's Disease and disturbances of the extrapyramidal system; pharmaceuticals for psychotropic, rhinologic and sinositic purposes; pharmaceuticals functioning as roborants and tonics; pharmaceuticals for use in thyroidal therapeutics; pharmaceuticals functioning as spasmolytics and inhibitors of thrombocyte aggregation; pharmaceuticals for the treatment of tuberculosis; pharmaceuticals functioning as alternants, urologics and venous agents; vitamins; pharmaceuticals for use as cytostatics and antineoplastic agents; homeopathic remedies, and medical plastics, namely sanitary preparations, veterinary preparations for use in the treatment of diseases of pets, livestock, wild animals, breeding animals and zoo animals; dietic supplements adapted for medical use, namely food for elderly people and for medically restricted diets; all-purpose disinfectants; preparations for destroying vermin; fungicides for domestic use; fungicides for agricultural use; herbicides for domestic use; herbicides for agricultural use; medicaments against artheriosclerosis; medicaments against restenosis; medicaments for tissue regeneration and tissue replacement; medicaments for cartilage regeneration; pharmaceutical and veterinary preparations for diabetes treatment; pharmaceutical and veterinary preparations for diabetes prophylaxis; medicaments against obesity; pharmaceutical and veterinary preparations for use in pets, livestock, wild animals, breeding animals and zoo animals against tumors; peptides for medical use; peptides for medical diagnostic use; peptidomimetics for medical use; peptiomimetics for medical diagnostic use; antibodies for medical use; antibodies for medical diagnostic use; DNA probes for medical use; DNA probes for medical diagnostic use; oligonucleotides for medical use; oligonucleotides for medical diagnostic use; small molecules for medical use | SECTION 8 - CANCELLED | — |
| 009 | Scientific control apparatus and instruments, namely microscopes, ELISA readers, scanners, fluorescence readers, and phosphorimagers; scientific measuring and checking apparatus and instruments, comprising filters and membranes used in the field of biotechnology and pharmaceuticals; computer programs for synthesis of chemicals used in industry and science; computer programs for immobilization of chemicals used in industry and science; computer programs for analysis of patterns on surfaces, namely for analysis of filters and membranes; computer programs for the screening of compounds | SECTION 8 - CANCELLED | — |
| 040 | Chemical processing or transformation of inorganic or organic compounds for third parties, namely synthesis of peptides, polypeptides and proteins, manufacture of immobilized enzyme substrates, proteinmimetica and peptidimimetica, synthesis of peptides with sterically hindered amino acids, synthesis of peptides with distinct secondary structures and/or multiple antigenic peptides, immobilization of products and compounds, compound libraries, enzyme substrates, proteinmimetica and peptidomimetica, modification of peptides and proteins, and transformation of biologically active peptides and peptidomimetica | SECTION 8 - CANCELLED | — |
| 042 | Laboratory services of a chemist, biologist, biochemist, biotechnologists, gene technologists, molecular biologists, pharmacists, medical doctor, protein chemist; scientific and industrial research; computer programming | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by RUDOWER CHAUSSEE 29 12489
- Other trademarks owned by RUDOWER CHAUSSEE 29 12489
- Other trademarks owned by RUDOWER CHAUSSEE 29 12489
- Other trademarks owned by Jerini Bio Tools GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named JERINI
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 20, 2011 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Feb 3, 2010 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 3, 2010 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 24, 2007 | CORV | REVIEW OF CORRESPONDENCE COMPLETE | — |
| Oct 18, 2007 | PAPER RECEIVED | — | |
| Dec 11, 2004 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 9, 2004 | PAPER RECEIVED | — | |
| Nov 8, 2004 | PAPER RECEIVED | — | |
| Oct 19, 2004 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Oct 19, 2004 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 27, 2004 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 19, 2004 | PAPER RECEIVED | — | |
| Jul 7, 2004 | NPUB | NOTICE OF PUBLICATION | — |
| Jun 18, 2004 | PAPER RECEIVED | — | |
| Apr 20, 2004 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 20, 2004 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| Apr 20, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 5, 2004 | FAXX | FAX SENT | — |
| Feb 25, 2004 | PAPER RECEIVED | — | |
| Feb 17, 2004 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 23, 2004 | CFIT | CASE FILE IN TICRS | — |
| Jan 20, 2004 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Jan 20, 2004 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Jan 12, 2004 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Sep 11, 2003 | PAPER RECEIVED | — | |
| Mar 12, 2003 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 3, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 3, 2003 | PAPER RECEIVED | — | |
| Jan 15, 2003 | CNSI | INQUIRY AS TO SUSPENSION MAILED | — |
| Jun 18, 2002 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Mar 12, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 11, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 11, 2002 | PAPER RECEIVED | — | |
| Mar 1, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 1, 2002 | PAPER RECEIVED | — | |
| Aug 27, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 20, 2001 | DOCK | ASSIGNED TO EXAMINER | — |